The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1682
ISSUE 1682
August 7, 2023
Issue 1682
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Drugs for Anxiety Disorders
August 7, 2023 (Issue: 1682)
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or...more
- US Preventive Services Task Force. Screening for anxiety disorders in adults: US Preventive Services Task Force recommendation statement. JAMA 2023; 329:2163. doi:10.1001/jama.2023.9301
- KL Szuhany and NM Simon. Anxiety disorders: a review. JAMA 2022; 328:2431. doi:10.1001/jama.2022.22744
- A Garakani et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Focus (Am Psychiatr Publ) 2021; 19:222. doi:10.1176/appi.focus.19203
- NH Kalin. The critical relationship between anxiety and depression. Am J Psychiatry 2020; 177:365. doi:10.1176/appi.ajp.2020.20030305
- Drugs for depression. Med Lett Drugs Ther 2020; 62:25.
- RL Woosley and KA Romero. QT drugs list. Available at: www.crediblemeds.org.
- Citalopram, escitalopram, and the QT interval. Med Lett Drugs Ther 2013; 55:59.
- L De Picker et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics 2014; 55:536. doi:10.1016/j.psym.2014.01.010
- SB Gumusoglu et al. Selective serotonin reuptake inhibitors and preeclampsia: a quality assessment and meta-analysis. Pregnancy Hypertens 2022; 30:36. doi:10.1016/j.preghy.2022.08.001
- O Stephansson et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309:48. doi:10.1001/jama.2012.153812.
- A Berard et al. Paroxetine use during pregnancy and perinatal outcomes including types of cardiac malformations in Quebec and France: a short communication. Curr Drug Saf 2012; 7:207. doi:10.2174/157488612803251360
- Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Available at: http://bitly.ws/LJaV. Accessed July 20, 2023.
- C Bellantuono et al. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol 2015; 30:143. doi:10.1002/hup.2473
- N Chawla et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ 2022; 376: e066084. doi:10.1136/bmj-2021-066084
- In brief: New benzodiazepine warnings. Med Lett Drugs Ther 2020; 62:175.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- CL Mattson et al. Opportunities to prevent overdose deaths involving prescriptions and illicit opioids, 11 states, July 2016-June 2017. MMWR Morb Mortal Wkly Rep 2018; 67:945. doi:10.15585/mmwr.mm6734a2
- I Hernandez et al. Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries. JAMA Netw Open 2018; 1:e180919. doi:10.1001/jamanetworkopen.2018.0919
- O Sheehy et al. Association between incident exposure to benzodiazepines in early pregnancy and risk of spontaneous abortion. JAMA Psychiatry 2019; 76:948. doi:10.1001/jamapsychiatry.2019.0963
- SC Tinker et al. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. Birth Defects Res 2019; 111:613. doi:10.1002/bdr2.1497
- BN Wikner et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1203. doi:10.1002/pds.1457
- ACOG Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. doi:10.1097/aog.0b013e31816fd910
- HK Greenblatt and DJ Greenblatt. Gabapentin and pregabalin for the treatment of anxiety disorders. Clin Pharmacol Drug Dev 2018; 7:228. doi:10.1002/cpdd.446
- B Bandelow. Current and novel psychopharmacological drugs for anxiety disorders. Adv Exp Med Biol 2020; 1191:347. doi:10.1007/978-981-32-9705-0_19
- M Markota and RJ Morgan. Treatment of generalized anxiety disorder with gabapentin. Case Rep Psychiatry 2017; 2017:6045017. doi:10.1155/2017/6045017
- In brief: Respiratory depression with gabapentinoids. Med Lett Drugs Ther 2020; 62:81.
- N Mokhber et al. Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin Neurosci 2010; 64:128. doi:10.1111/j.1440-1819.2009.02055.x
- CA Chessick et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; 3:CD006115. doi:10.1002/14651858.cd006115
- MP Freeman et al. Pregnancy outcomes after first-trimester exposure to buspirone: prospective longitudinal outcomes from the MGH National Pregnancy Registry for psychiatric medications. Arch Womens Ment Health 2022; 25:923. doi:10.1007/s00737-022-01250-8
- CAC Coupland et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 2019; 179:1084. doi:10.1001/jamainternmed.2019.0677
- C Blanco et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010; 67:286. doi:10.1001/archgenpsychiatry.2010.11
- DV Sheehan. Current concepts in psychiatry. Panic attacks and phobias. N Engl J Med 1982; 307:156. doi:10.1056/nejm198207153070304
- N Maneeton et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2016; 10:259. doi:10.2147/dddt.s89485
- T-JM Kreys and SV Phan. A literature review of quetiapine for generalized anxiety disorder. Pharmacotherapy 2015; 35:175. doi:10.1002/phar.1529
- TG Boyce et al. The use of β-adrenergic receptor antagonists in psychiatry: a review. J Acad Consult Liaison Psychiatry 2021; 62:404. doi:10.1016/j.jaclp.2020.12.009
- G Guaiana et al. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev 2010; 12:CD006815. doi:10.1002/14651858.cd006815.pub2
- JL Tully et al. Ketamine treatment for refractory anxiety: a systematic review. Br J Clin Pharmacol 2022; 88:4412. doi:10.1111/bcp.15374
- N Black et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6:995. doi:10.1016/s2215-0366(19)30401-8
- PA Cohen et al. Quantity of melatonin and CBD in melatonin gummies sold in the US. JAMA 2023; 329:1401. doi:10.1001/jama.2023.2296
- CM Kwee et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. Eur Neuropsychopharmacol 2022; 59:58. doi:10.1016/j.euroneuro.2022.04.003
- K Smith and C Leiras. The effectiveness and safety of kava kava for treating anxiety symptoms: a systematic review and analysis of randomized clinical trials. Complement Ther Clin Pract 2018; 33:107. doi:10.1016/j.ctcp.2018.09.003
- Ashwagandha supplements. Med Lett Drugs Ther 2021; 63:39.
- C Akhgarjand et al. Does ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res 2022; 36:4115. doi:10.1002/ptr.7598
- JV Olthius et al. Therapist-supported internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev 2016; 3:CD011565. doi:10.1002/14651858.cd011565.pub2
- JE Curtiss et al. Cognitive-behavioral treatments for anxiety and stress-related disorders. Focus (Am Psychiatr Publ) 2021; 19:184. doi:10.1176/appi.focus.20200045
- EA Hoge et al. Mindfulness-based stress reduction vs escitalopram for the treatment of adults with anxiety disorders: a randomized clinical trial JAMA Psychiatry 2023; 80:13. doi:10.1001/jamapsychiatry.2022.3679
- HJ Lee and MB Stein. Update on treatments for anxiety-related disorders. Curr Opin Psychiatry 2023; 36:140. doi:10.1097/yco.0000000000000841
- CP Ramos-Sanchez et al. The anxiolytic effects of exercise for people with anxiety and related disorders: an update of the available meta-analytic evidence. Psychiatry Res 2021; 302:114046. doi:10.1016/j.psychres.2021.114046
- M Li et al. Efficacy of acupuncture for generalized anxiety disorder: a PRISMA-compliant systematic review and metaanalysis. Medicine (Baltimore) 2022; 101:e30076. doi:10.1097/md.0000000000030076
- NM Simon et al. Efficacy of yoga vs cognitive behavioral therapy vs stress education for the treatment of generalized anxiety disorder: a randomized clinical trial. JAMA Psychiatry 2021; 78:13. doi:10.1001/jamapsychiatry.2020.2496
- J Cox et al. Repetitive transcranial magnetic stimulation for generalized anxiety and panic disorders: a systematic review and meta-analysis. Ann Clin Psychiatry 2022 34:e2. doi:10.12788/acp.0067
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1682
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.